Palisade Bio (PALI) Common Equity (2010 - 2026)

Palisade Bio (PALI) has 17 years of Common Equity data on file, last reported at $127.4 million in Q1 2026.

• On a quarterly basis, Common Equity rose 2289.08% year-over-year to $127.4 million in Q1 2026; TTM through Mar 2026 was $127.4 million, a 2289.08% increase from a year earlier, with the FY2025 full-year figure at $129.4 million, up 1626.91% from the prior year.
• Common Equity for Q1 2026 stood at $127.4 million, down from $129.4 million in the prior quarter.
• Over the last five years, Common Equity for PALI reached as high as $129.4 million in Q4 2025 and fell as low as $2.6 million in Q2 2025.
• Historically, Common Equity has averaged $23.0 million across 5 years, with a median of $10.1 million in 2024.
• Across the five-year window, Common Equity plunged 73.67% in 2025 and surged 2289.08% in 2026, its largest moves.
• Year by year, Common Equity stood at $12.5 million in 2022, then retreated by 9.34% to $11.3 million in 2023, then sank by 33.78% to $7.5 million in 2024, then surged by 1626.91% to $129.4 million in 2025, then dropped by 1.56% to $127.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $127.4 million in Q1 2026, $129.4 million in Q4 2025, and $3.2 million in Q3 2025.